HT-101

Hepa Thera Hepa Thera Hepa Thera Hepa Thera Hepa Thera Recently, HepaThera, as one of the core responsible units, participated in the kick-off meeting for the National Key Science and Technology Major Project—"Key Mechanisms, Predictive Biomarkers, and Novel Therapeutic Interventions for Achieving Functional Cure of Chronic Hepatitis B"—led by Fudan University. Recently, HepaThera, as one of the core responsible units, participated in the kick-off meeting for the National Key Science and Technology Major Project—"Key Mechanisms, Predictive Biomarkers, and Novel Therapeutic Interventions for Achieving Functional Cure of Chronic Hepatitis B"—led by Fudan University. Recently, HepaThera, as one of the core responsible units, participated in the kick-off meeting for the National Key Science and Technology Major Project—"Key Mechanisms, Predictive Biomarkers, and Novel Therapeutic Interventions for Achieving Functional Cure of Chronic Hepatitis B"—led by Fudan University. Ⅰ Principal Lead. End-to-End Breakthrough. Ⅰ Ⅰ Principal Lead. End-to-End Breakthrough. Principal Lead. End-to-End Breakthrough. Principal Lead. End-to-End Breakthrough. Principal Lead. End-to-End Breakthrough. In this project, HepaThera​ serves as the core industrial lead, collaborating with top-tier domestic institutions such as Fudan University, leading research academies, and tertiary hospitals to establish an end-to-end R&D platform. The company spearheads Task Four—"Novel Immunotherapy-Based Strategies for Chronic Hepatitis B Intervention"—driving the full pipeline from target discovery to clinical implementation, leveraging its robust expertise in liver disease innovation. In this project, HepaThera​ serves as the core industrial lead, collaborating with top-tier domestic institutions such as Fudan University, leading research academies, and tertiary hospitals to establish an end-to-end R&D platform. The company spearheads Task Four—"Novel Immunotherapy-Based Strategies for Chronic Hepatitis B Intervention"—driving the full pipeline from target discovery to clinical implementation, leveraging its robust expertise in liver disease innovation. In this project, HepaThera​ serves as the core industrial lead, collaborating with top-tier domestic institutions such as Fudan University, leading research academies, and tertiary hospitals to establish an end-to-end R&D platform. The company spearheads Task Four—"Novel Immunotherapy-Based Strategies for Chronic Hepatitis B Intervention"—driving the full pipeline from target discovery to clinical implementation, leveraging its robust expertise in liver disease innovation. Ⅱ Tackling Unmet Medical Needs. Embracing the Industry Mandate. Ⅱ Ⅱ Tackling Unmet Medical Needs. Embracing the Industry Mandate. Tackling Unmet Medical Needs. Embracing the Industry Mandate. Tackling Unmet Medical Needs. Embracing the Industry Mandate. Tackling Unmet Medical Needs. Embracing the Industry Mandate. Chronic hepatitis B remains a critical public health challenge in China. Current treatments are largely limited to viral suppression and rarely achieve a functional cure. The official kick-off of this national project marks the transition into a phase of collaborative R&D. Leveraging its robust pipeline and strong clinical translation capabilities, HepaThera​ will work in close partnership with leading institutions to advance the development and validation of novel functional cure regimens for CHB, thereby supporting the realization of the "Healthy China 2030"​ initiative. Chronic hepatitis B remains a critical public health challenge in China. Current treatments are largely limited to viral suppression and rarely achieve a functional cure. The official kick-off of this national project marks the transition into a phase of collaborative R&D. Leveraging its robust pipeline and strong clinical translation capabilities, HepaThera​ will work in close partnership with leading institutions to advance the development and validation of novel functional cure regimens for CHB, thereby supporting the realization of the "Healthy China 2030"​ initiative. About Us Hepa Thera HepaThera Biopharmaceutical Co., Ltd. was established in May 2021 as a biotechnology company focused on the development of innovative drugs in the field of liver disease therapeutics. The company's core pipeline for the functional cure of hepatitis B, HT-101 (a GalNAc-conjugated siRNA) and HT-102 (a fully human monoclonal antibody), has advanced to Phase II clinical trials and received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). The company is also actively expanding into the broader liver disease market, including MASH and liver cancer, with a strategic focus on cutting-edge technologies such as RNA interference, antibody-drug conjugates, and cell therapy. HepaThera is committed to building an innovative drug pipeline covering the entire cycle of "antiviral, anti-fibrotic, and anti-tumor" therapies, aspiring to become a platform company with significant influence in the field of liver disease treatment. About Us Hepa Thera HepaThera Biopharmaceutical Co., Ltd. was established in May 2021 as a biotechnology company focused on the development of innovative drugs in the field of liver disease therapeutics. The company's core pipeline for the functional cure of hepatitis B, HT-101 (a GalNAc-conjugated siRNA) and HT-102 (a fully human monoclonal antibody), has advanced to Phase II clinical trials and received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). The company is also actively expanding into the broader liver disease market, including MASH and liver cancer, with a strategic focus on cutting-edge technologies such as RNA interference, antibody-drug conjugates, and cell therapy. HepaThera is committed to building an innovative drug pipeline covering the entire cycle of "antiviral, anti-fibrotic, and anti-tumor" therapies, aspiring to become a platform company with significant influence in the field of liver disease treatment. About Us Hepa Thera About Us About Us Hepa Thera Hepa Thera Hepa Thera Hepa Thera HepaThera Biopharmaceutical Co., Ltd. was established in May 2021 as a biotechnology company focused on the development of innovative drugs in the field of liver disease therapeutics. The company's core pipeline for the functional cure of hepatitis B, HT-101 (a GalNAc-conjugated siRNA) and HT-102 (a fully human monoclonal antibody), has advanced to Phase II clinical trials and received Breakthrough Therapy Designation from the National Medical Products Administration (NMPA). The company is also actively expanding into the broader liver disease market, including MASH and liver cancer, with a strategic focus on cutting-edge technologies such as RNA interference, antibody-drug conjugates, and cell therapy. HepaThera is committed to building an innovative drug pipeline covering the entire cycle of "antiviral, anti-fibrotic, and anti-tumor" therapies, aspiring to become a platform company with significant influence in the field of liver disease treatment.